Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
TOKYO and SAN DIEGO, Jan. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Vical Incorporated (NASDAQ: VICL) announced today that ASP0113, an investigat... Biopharmaceuticals Astellas Pharma, Vical , cytomegalovirus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cytomegalovirus | Marketing | Pharmaceuticals | Stem Cell Therapy | Stem Cells | Transplants | Vaccines